Market News

Zions Bancorporation (ZION) Shareholder Elizabeth Park Capital Advisors LTD Has Trimmed Position by $564,000; Proquest Associates Iv Has Decreased Its Stake in Immune Design Corp. (IMDZ) as Shares Rose

Fred Cummings decreased its stake in Zions Bancorporation (ZION) by 4.43% based on its latest 2017Q3 regulatory filing with the SEC. Elizabeth Park Capital Advisors Ltd sold 12,000 shares as the company’s stock declined 10.19% while stock markets rallied. The hedge fund run by Fred Cummings held 258,852 shares of the major banks company at the end of 2017Q3, valued at $12.21M, down from 270,852 at the end of the previous reported quarter. Elizabeth Park Capital Advisors Ltd who had been investing in Zions Bancorporation for a number of months, seems to be less bullish one the $10.88B market cap company. The stock increased 0.55% or $0.3 during the last trading session, reaching $55.07. About 2.34M shares traded. Zions Bancorporation (NASDAQ:ZION) has risen 48.85% since February 18, 2017 and is uptrending. It has outperformed by 32.15% the S&P500.

Proquest Associates Iv Llc decreased its stake in Immune Design Corp. (IMDZ) by 27.99% based on its latest 2017Q3 regulatory filing with the SEC. Proquest Associates Iv Llc sold 549,440 shares as the company’s stock rose 32.73% with the market. The institutional investor held 1.41M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $14.63M, down from 1.96M at the end of the previous reported quarter. Proquest Associates Iv Llc who had been investing in Immune Design Corp. for a number of months, seems to be less bullish one the $161.00M market cap company. The stock decreased 2.90% or $0.1 during the last trading session, reaching $3.35. About 433,235 shares traded. Immune Design Corp. (NASDAQ:IMDZ) has declined 40.11% since February 18, 2017 and is downtrending. It has underperformed by 56.81% the S&P500.

Investors sentiment decreased to 1.05 in 2017 Q3. Its down 0.04, from 1.09 in 2017Q2. It turned negative, as 45 investors sold ZION shares while 132 reduced holdings. 54 funds opened positions while 131 raised stakes. 181.27 million shares or 1.35% less from 183.76 million shares in 2017Q2 were reported. Jacobs Levy Equity Mngmt Inc owns 0.26% invested in Zions Bancorporation (NASDAQ:ZION) for 283,460 shares. Thrivent Fin For Lutherans holds 4.33 million shares. Profund Advsr holds 7,353 shares or 0.01% of its portfolio. Denver Inv Advsrs Ltd Liability Co owns 19,871 shares for 0.05% of their portfolio. Ls Invest Limited Liability Corporation reported 9,823 shares. Pnc Fin Svcs holds 0.01% or 251,796 shares. Petrus Tru Lta owns 4,773 shares for 0.05% of their portfolio. Kennedy Mngmt, a Missouri-based fund reported 243,740 shares. Etrade Capital Management Limited Liability Company has 0.04% invested in Zions Bancorporation (NASDAQ:ZION) for 25,312 shares. 122,574 are held by Robeco Institutional Asset Mgmt Bv. The Netherlands-based Ing Groep Nv has invested 0.01% in Zions Bancorporation (NASDAQ:ZION). Minnesota-based Sit Invest Assocs has invested 0% in Zions Bancorporation (NASDAQ:ZION). Capital Fund, a France-based fund reported 236,153 shares. Palisades Hudson Asset Limited Partnership holds 0.16% in Zions Bancorporation (NASDAQ:ZION) or 6,118 shares. Raymond James & Assoc reported 42,857 shares.

Among 30 analysts covering Zions Bancorporation (NASDAQ:ZION), 16 have Buy rating, 1 Sell and 13 Hold. Therefore 53% are positive. Zions Bancorporation had 122 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Outperform” rating by FBR Capital on Tuesday, December 20. FBR Capital maintained Zions Bancorporation (NASDAQ:ZION) on Monday, November 20 with “Buy” rating. The stock of Zions Bancorporation (NASDAQ:ZION) earned “Buy” rating by Raymond James on Tuesday, September 13. The stock has “Hold” rating by BMO Capital Markets on Tuesday, January 23. FBR Capital maintained it with “Mkt Perform” rating and $42 target in Friday, December 2 report. On Thursday, December 21 the stock rating was maintained by Keefe Bruyette & Woods with “Buy”. The rating was initiated by JMP Securities on Thursday, February 2 with “Mkt Perform”. The firm earned “Mkt Perform” rating on Thursday, October 6 by Raymond James. The stock of Zions Bancorporation (NASDAQ:ZION) earned “Outperform” rating by Bernstein on Tuesday, April 26. The firm has “Hold” rating by Keefe Bruyette & Woods given on Tuesday, October 3.

Since August 14, 2017, it had 0 insider buys, and 3 sales for $1.22 million activity. $764,781 worth of Zions Bancorporation (NASDAQ:ZION) shares were sold by Young Mark Richard. Another trade for 7,196 shares valued at $387,649 was sold by Hume Alexander. 13,000 shares valued at $584,717 were sold by Schreiber Edward on Monday, August 14. $67,844 worth of Zions Bancorporation (NASDAQ:ZION) was sold by LAURSEN THOMAS E on Wednesday, January 31.

Elizabeth Park Capital Advisors Ltd, which manages about $166.10 million and $257.67 million US Long portfolio, upped its stake in Pinnacle Finl Partners Inc (NASDAQ:PNFP) by 45,000 shares to 182,418 shares, valued at $12.21 million in 2017Q3, according to the filing. It also increased its holding in Southern First Bancshares In (NASDAQ:SFST) by 18,621 shares in the quarter, for a total of 31,189 shares, and has risen its stake in Macatawa Bk Corp (NASDAQ:MCBC).

Since October 27, 2017, it had 2 buys, and 5 selling transactions for $21.92 million activity. Brady Stephen R sold $13,885 worth of stock. 2.68M Immune Design Corp. (NASDAQ:IMDZ) shares with value of $10.99 million were bought by Svennilson Peter. $10.99 million worth of stock was bought by COLUMN GROUP LP on Friday, October 27. ter Meulen Jan Henrik sold $8,282 worth of stock. 7,970 shares were sold by Paya Carlos V, worth $33,247 on Thursday, January 4. Yurasov Sergey also sold $2,816 worth of Immune Design Corp. (NASDAQ:IMDZ) shares.

Investors sentiment decreased to 1.27 in 2017 Q3. Its down 1.17, from 2.44 in 2017Q2. It dropped, as 5 investors sold IMDZ shares while 21 reduced holdings. 13 funds opened positions while 20 raised stakes. 11.88 million shares or 8.39% more from 10.96 million shares in 2017Q2 were reported. Legal And General Group Public Limited Co has invested 0% in Immune Design Corp. (NASDAQ:IMDZ). Trexquant Investment LP owns 14,260 shares. The United Kingdom-based Abingworth Ltd Liability Partnership has invested 2.52% in Immune Design Corp. (NASDAQ:IMDZ). Vanguard Gru invested in 0% or 602,720 shares. Renaissance Technologies Limited Liability Co invested in 123,591 shares or 0% of the stock. Mufg Americas Corp invested in 271 shares or 0% of the stock. D E Shaw Communication reported 0% stake. Barclays Public Limited holds 12,296 shares. State Street accumulated 0% or 221,490 shares. Thompson Davis And stated it has 250 shares. Royal National Bank & Trust Of Canada has 1,602 shares for 0% of their portfolio. Jpmorgan Chase & holds 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ) for 504,675 shares. Schwab Charles Invest holds 34,143 shares or 0% of its portfolio. Geode Capital Management Lc stated it has 0% in Immune Design Corp. (NASDAQ:IMDZ). Citigroup owns 31 shares or 0% of their US portfolio.

Among 5 analysts covering Immune Design (NASDAQ:IMDZ), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Immune Design had 10 analyst reports since August 18, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with “Buy” rating in Tuesday, June 6 report. The firm has “Outperform” rating by Leerink Swann given on Tuesday, August 18. Jefferies maintained it with “Buy” rating and $18.0 target in Monday, September 4 report. Jefferies initiated Immune Design Corp. (NASDAQ:IMDZ) on Wednesday, September 9 with “Buy” rating. Jefferies maintained Immune Design Corp. (NASDAQ:IMDZ) on Monday, June 26 with “Buy” rating. The rating was maintained by Wells Fargo on Wednesday, October 18 with “Market Perform”. The firm earned “Buy” rating on Thursday, October 5 by Jefferies. The rating was maintained by Jefferies on Wednesday, August 10 with “Buy”.

Analysts await Immune Design Corp. (NASDAQ:IMDZ) to report earnings on March, 6. They expect $-0.39 earnings per share, up 31.58% or $0.18 from last year’s $-0.57 per share. After $-0.52 actual earnings per share reported by Immune Design Corp. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

Leave a Reply

Your email address will not be published. Required fields are marked *